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Abstract – As a continuation of our previous work turned toward the identification of 
antimycobaterial compounds with innovative structure, two series of pyrazole derivatives were 
synthesized by parallel solution-phase synthesis and assayed as inhibitors of Mycobacterium 
tuberculosis (MTB), the causative agent of tuberculosis. One of these compounds showed high 
activity against MTB (MIC = 4 μg/mL). The newly synthesized pyrazoles were also 
computationally investigated to analyse their fit properties to the pharmacophoric model for 
antitubercular compounds previously built by us and to refine structure-activity relationship 
analysis. 
 
 
1. Introduction 
 
Tuberculosis (TB) is an airborne infectious disease caused by Mycobacterium tuberculosis 
(MTB) and represents one of the leading causes of death worldwide. The World Health 
Organization (WHO) estimates that in 2005 8.8 million people fell ill with TB and 1.6 million of 
them died.
 
The dangerous spread of TB is mainly due to its association with HIV infection and to 
the rapid development of multidrug-resistant (MDR) strains of MTB.
1
 Another most alarming 
aspect is the emergence in the last years of extensively drug-resistant TB (XDR-TB);
2 it poses a 
serious threat to TB control, and confirms the urgent need to discover new structural classes of 
antimycobacterial compounds in order to develop agents to replace or supplement the established 
drugs.
3 
Recently, we reported successful results on the identification of new antimycobaterial 
compounds with innovative structures through a computational procedure for the generation, design 
and screening of a ligand-based virtual library. A 5-hydroxy-pyrazole compound with general 
structure A, characterized by a MIC of 25 g mL-1, emerged as hit candidate from virtual screening. 
Consequent optimization of the hit and synthesis of  a library of derivatives led us to obtain 
pyrazoles 1-3 as interesting compounds with enhanced antimycobaterial activity, namely MIC of 
6.25 g mL-1 for 1 and 2 and MIC of 12.5 g mL-1 for 3 (Figure 1, Table 1).4 The major suggestion 
derived from biological results was that the p-chlorobenzoyl moiety at C4 of pyrazole ring with 
general structure A was fundamental for the activity. However, no investigations were carried out 
on the effects that the introduction of different substituents at N1, N2 and C3 of the pyrazole ring 
might produce on antimycobacterial activity. As a consequence, in the attempt to increase the fitting 
to the pharmacophoric model, and possibly to optimize the bind to the hypothetical receptor, we 
report here the synthesis, biological activity and SAR study of two series (I and II) of second  
generation pyrazole/pyrazolones derivatives. Series I, constituted by analogues of compounds 1-3 
(Figure 1), was designed to investigate on the influence exerted on the activity bysynthetic 
derivatizations at C3 and on the N1-phenyl ring, keeping fixed the  p-chlorobenzoyl moiety at C4, 
suggested to be crucial for the activity. On the other hand, series II was based on the structure of 
pyrazolone 4 previously synthesised by us altough its activity towards MTB was > 100 g mL-1. 
This series was based on the insertion of substituents at the N2 of the pyrazole ring, a position not 
investigated in previous antimycobacterialpyrazolone derivatives, while keeping fixed a methyl 
group at C3. In detail, following what reported in the literature about the importance of an 
additional aromatic group on the central pyrazole nucleus,
5
 different benzyl groups were chosen to 
be introduced at N2. 
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Figure 1. Hit compounds 1-3 and previous structure-activity relationship considerations 
 
 
 
2. Chemistry  
 
A series of analogues of 1-3 (series I) was synthesized in parallel using a Büchi Syncore 
synthesizer
4 
as illustrated in Scheme 1. -Ketoesters 5a-d were placed into 11 different reaction 
vessels and reacted in parallel with 5 different phenylhydrazines 6a-e. After the reactions were 
completed, p-toluensulfonic acid polymer bound scavenger was added to remove te excess of 
hydrazines and the mixtures were filtered in parallel to afford compounds 7a-k.
6
 They were 
obtained together with a small amount of their regioisomers resulting from attack of hydrazines first 
on ester moiety and then on ketone moiety. Separation of the two regioisomers was possible by 
fractionate crystallization from an appropriate solvent.
 
Reaction of desired pyrazolones with p-
chlorobenzoyl chloride using the Jensen method afforded pyrazoles 8a-k.
7
 These compounds were 
obtained in high yield after simple filtration-recrystallization procedure from the crude mixtures.  
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Scheme 1. Reagents and conditions: i. a) Syncore, 300 rpm, EtOH, reflux; b) p-toluensulfonic acid polymer bound. ii. 
p-Cl-C6H4COCl, Ca(OH)2, Syncore, 300 rpm, dioxane, reflux.  
 
 
On the other hand, based on the knowledge that pyrazolones bearing three aromatic groups 
resulted to be active toward a wide range of bacteria,
5
 a serie of N-2-benzyl derivatives 9a-f  (series 
II) was then synthesised starting from leads 1 and 2. The aim of this second series was to 
investigate the effects that large and aromatic groups at N2, such as a benzyl group, might have on 
the antimycobaterial activity. Pyrazoles 1 and 2 were placed into 6 different reaction vessels and 
reacted in parallel with different benzyl halides using a Büchi Syncore synthesizer affording 
pyrazolones 9a-f.
8,9 
The N2-alkylated derivatives were formed as the only products under these 
reaction conditions. No traces of O-alkylated isomers were observed. NOE experiments confirmed 
that the alkylation proceeded only at N2.
10
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Scheme 2. Reagents and conditions: i. Benzyl halide, NaH, DMF, 60 °C, Syncore, 300 rpm. 
 
 
 
3. Results and Discussion 
  
Compounds were assayed for their inhibitory activity toward M. tuberculosis H37Rv 
(ATCC27294). The minimum inhibitory concentration (µg mL
-1
) was determined for each 
compound (Table 1). 
 
Table1. 
N N
R1
O
OH
Cl
R
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N
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4 and 9a-f1-3 and 8a-k
Series I Series II
 
Compd R R1 
 
MIC (μg/mL) 
M. tuberculosis 
1 Cl CH3 6.25 
2 H CH3 6.25 
3 F CH3 12.5 
8a H CF3 >64 
8b H isopropyl 64 
8c H Ph 32 
8d Cl CF3 >64 
8e Cl isopropyl 32 
8f Cl Ph 16 
8g Br CH3 4 
8h CH3 CH3 16 
8i CH3 Ph 32 
8j isopropyl CH3 16 
8k isopropyl Ph 32 
4 H CH3 >100 
9a H 4-F-Bn 32 
9b H Bn >64 
9c H 4-NO2-Bn >32 
9d Cl 4-F-Bn 32 
9e Cl Bn 16 
9f Cl 4-NO2-Bn 32 
 
 
 
With regard to compounds 8a-k, the introduction at C3 of groups different from the methyl 
substituent was in general detrimental for activity, and never led to an improvement of the MIC 
values. The maintenance of a methyl group at C3, as in compounds 8g, 8h and 8j, resulted in 
medium or good activity values. Different hydrophobic substituents at para position of the N1-
phenyl ring were tolerated. The pyrazole derivative 8g, with the p-bromophenyl group at N1 
position showed to be very active (MIC = 4 μg/mL), with a slightly higher activity than hit 
compounds 1 and 2. Conversely,  pyrazolone derivatives 9a-f, keeping fixed the methyl group at C3 
and bearing a 4-substituted-benzyl moiety at N2, resulted to be significantly more active than the 
methyl derivative 4, even if they resulted to be less active than the pyrazole series. 
 
4. Computational studies 
 
The newly synthesized pyrazole derivatives were computationally investigated by means of the 
Catalyst software,
11
 to analyze their fit properties to the pharmacophoric model for antitubercular 
compounds previously built.
12
 Such a pharmacophore, consisting of two ring aromatic (RA1 and 
RA2), two hydrophobic (HY1 and HY2) and one hydrogen bond acceptor (HBA) features, was part 
of the virtual screening procedure which resulted in the discovery of the hit compound 1.
4
 As a 
result of the computational analysis, all the derivatives 8a-k were found to map the pharmacophoric 
model with a very similar orientation, closely resembling that of compound 1 (Figure 2). In detail, 
the pyrazole nucleus appeared to act as a scaffold to direct the phenyl moiety at N1 and the benzoyl 
moiety at C4 in the proper region of space, resulting in efficacious fitting of RA1 and RA2 features, 
respectively. The carbonyl group of each pyrazole derivative corresponded to the HBA feature of 
the pharmacophore. The methyl group at C3 was well accommodated into the hydrophobic region 
HY2, thus accounting for the good activity generally associated with the presence of a methyl 
substituent at this position. Introduction of bulkier hydrophobic substituents at C3, which still 
mapped but exceeded the HY2 function, resulted in compounds with decreased activity, suggesting 
that this region may be involved in a favourable hydrophobic interaction with the receptor 
counterpart, but unfavourable steric interactions could occur upon increasing the substituent size. 
The halogen or alkyl substituents at the para position of the phenyl ring at N1 of derivatives 8d-k 
well fitted the second hydrophobic region of the pharmacophoric model, namely HY1. However, it 
resulted that N1-phenyl-halogenated derivatives (namely 1, 8f and 8g) were more active than the 
corresponding N1-phenyl-alkyl compounds 8h-k, keeping fixed the substituent at C3. We might 
assume that the electronic nature of halogens on phenyl ring had a benefit effect resulting in 
compounds with enhanced antimycobaterial activity. On the contrary, the presence in the same 
position of an electron-donating group, such as methyl or isopropyl group, resulted into a medium-
high loss of activity. Among the different hydrophobic groups, the highest activity measured for 8g 
indicated the bromine substituent as the most suitable at this position.
13 
The complete lack of 
activity of compound 8f, bearing a chlorine at the para position of the phenyl ring and a trifluoro 
substituent at C3 (able to fit the hydrophobic functions), was quite unexpected and could not be 
explained only with the spatial and functional information provided by the pharmacophoric model. 
Maybe the electron withdrawing nature of trifluoro substituent produces an electronic 
destabilization of the pyrazole nucleus, resulting somehow in a loss of activity. On the basis of 
these speculations, it seems obvious that the electronic properties of the pyrazole derivatives play a 
crucial role in order to enhance the antimycobacterial activity. 
 
 
Figure 2. Superposition of compound 1 (red) and 8g (blue) onto the pharmacophoric model for antitubercular 
compounds. Features are color-coded (cyan: hydrophobic; orange: aromatic ring; green: hydrogen bond acceptor). 
 
On the other hand, the presence of a large benzyl substituent at N2 in compounds 9a-f induced a 
rearrangement into the pharmacophoric model and a completely different mapping with respect to 
derivatives 8a-k (Figure 3). In more detail, the methyl group at C3 was still located into the 
hydrophobic region HY2, similarly to compounds 8a-k, while the HY1 and RA1 features were 
matched by the p-chlorobenzoyl group, and the benzyl moiety fitted well the RA2 function. The 
para-substituted phenyl ring at N1, emerged as important in modulating the activity in the previous 
set of compounds, was not relevant for interacting with the pharmacophoric elements. Finally, the 
HBA feature was mapped by the carbonyl group of the pyrazolone nucleus, a motif which was 
absent in derivatives 8a-k. Remarkably, the substituents discriminating among compounds 9a-f 
(namely, those at the para positions of the phenyl ring at N1 and the benzyl group at N2) were 
placed in a region of space where no pharmacophoric feature lies. This aspect impeded us to use the 
pharmacophoric model as a tool to rationalize the differences in activity detected for derivatives 9a-
f. 
 
 
Figure 3. Compound 9e mapped to the pharmacophoric model. The color and orientation of features are the same as in 
Figure 2. 
 
 
 
5. Experimental  
 
Reagents were obtained from commercial suppliers and used without further purification. Dioxane 
was dried over Na/benzophenone prior to use. Anydrous reactions were run under a positive 
pressure of dry N2. Merck silica gel 60 was used for flash chromatography (23-400 mesh). 
1
H NMR 
and 
13
C NMR spectra were measured at 200 MHz on a Bruker AC200F spectrometer and at 400 
MHz on a Bruker Avance DPX400. Chemical shifts are reported relative to CDCl3 at  7.24 ppm 
and tetramethylsilane at  0.00 ppm. Büchi Syncore polyvap was used fo parallel synthesis, 
filtration and evaporation. 
HPLC and MS analysis. The purity of compounds was assessed by reverse-phase liquid 
chromatography and a mass spectrometer (Agilent series 1100 LC/MSD) with a UV detector at λ = 
254 nm and an electrospray ionization source (ESI). All the solvents were HPLC grade (Fluka). 
Mass spectral (MS) data were obtained using an Agilent 1100 LC/MSD VL system (G1946C) with 
a 0.4 mL/min flow rate using a binary solvent system of 95:5 methyl alcohol/water. UV detection 
was monitored at 254 nm. Mass spectra were acquired in positive mode scanning over the mass 
range of 50-1500. The following ion source parameters were used: drying gas flow, 9 mL/min; 
nebulize pressure, 40 psig; drying gas temperature, 350 °C. 
 
Parallel synthesis of pyrazolones 7a-k. 
Appropriate β-ketoesters partioned into 11 different vessels (3 mmol) were placed in the Büchi 
Syncore
®
 and dissolved in EtOH (5 mL). Appropriate phenylhydrazines (3 mmol) were then added. 
The reaction mixtures were refluxed at 300 rpm for 3 h. To the cooled solutions, p-toluensulfonic 
acid polymer bound scavenger was added (0.2 equiv/mol) and the mixtures were stirred (300 rpm) 
for 2 h at rt. The reaction mixtures were filtered in parallel with a specific filtration unit and the 
scavengers were washed twice with CH2Cl2 (10 mL). The solvents were evaporated to dryness in 
the same apparatus. Compounds 7a-k were recrystallized from Et2O (40-60% yield after 
crystallization). After crystallization, compound 7a-k were identified by LC/MS analysis and 
proved to be pure enough (>90%) to be used in the next step without further purification. 
 
7a: Yield 40%. 
1
H NMR (CDCl3):  7.70-7.33 (5H, m, Ph), 5.90 (1H, s, CH), 3.35 (1H, br s, OH). 
MS: m/z 212 (M
+
).  
7b: Yield 48%. 
1
H NMR (CD3OD):  7.65-7.26 (5H, m, Ph), 3.34 (2H, s, CH2), 2.84 (1H, m, 
CH3CHCH3), 1.26 (6H, d, J = 6.9 Hz, CH3CHCH3). MS: m/z 203 (M
+
).  
7c: Yield 60%. 
1
H NMR (CD3OD):  7.96 (2H, m, Ph), 7.73 (2H, m, Ph), 7.69-7.22 (6H, m, Ph), 
3.73 (2H, s, CH2). MS: m/z 237 (M
+
).  
7d: Yield 46%. 
1
H NMR (CDCl3):  7.73 (2H, d, J = 8.8 Hz, Ph), 7.53 (2H, d, J = 8.8 Hz, Ph), 5.91 
(1H, s, CH), 3.30 (1H, br s, OH).   MS: m/z 247 (M
+
).  
7e: Yield 54%. 
1
H NMR (CD3OD):  7.55 (2H, d, J = 8.7 Hz, Ph), 7.35 (2H, d, J = 8.7 Hz, Ph), 
6.08 (1H, s, CH), 3.16 (1H, m, CH3CHCH3), 1,29 (6H, d, J = 6.9 Hz, CH3CHCH3). MS: m/z 237 
(M
+
).  
7f: Yield 60%. 
1
H NMR (CDCl3):  7.96-7.72 (4H, m, Ph), 7.50-7.28 (5H, m, Ph), 3.83 (2H, s, 
CH2). MS: m/z 271 (M
+
).  
7g: Yield 52%. 1H NMR (CDCl3):  (ppm) 7.78 (2H, d, J=9.3 Hz, Ph), 7.47 (2H, d, J=9.3 Hz, Ph), 
3.41 ( 2H, s, CCH2CO), 2.18 (3H, s, CH3). MS: m/z 253-255 (M+1)
+
, 275-277 (M+Na)
+
, 529-531 
(2M+Na)
+
.  
7h: Yield 60%. 
1
H NMR (CDCl3):  7.43 (2H, d, J = 8.0 Hz, Ph), 7.17 (2H, d, J = 8.0 Hz, Ph), 6.05 
(1H, s, CH), 2.35 (3H, s, CH3), 2.30 (3H, s, CH3). MS: m/z 189 (M
+
).  
7i: Yield 59%. 
1
H NMR (CDCl3):  7.83 (2H, m, Ph), 7.41-7.05 (7H, m, Ph), 3.81 (2H, s, CH2), 
2.14 (3H, s, CH3). MS: m/z 251 (M
+
).  
7j: Yield 52%. 
1
H NMR (CD3OD):  7.50-7.25 (5H, m, Ph), 5.59 (1H, s, CH), 2.90 (1H, m, 
CH3CHCH3), 2.19 (3H, s, CH3), 1.23 (6H, d, J = 6.8 Hz, CH3CHCH3). MS: m/z 217 (M
+
).  
7k: Yield 57%. 
1
H NMR (CDCl3):  7.83 (2H, m, Ph), 7.44-7.16 (7H, m, Ph), 3.82 (2H, s, CH2), 
2.77 (1H, m, CH3CHCH3), 1.10 (6H, d, J = 6.8 Hz, CH3CHCH3). MS: m/z 279 (M
+
).  
 Parallel synthesis of pyrazoles 8a-k.  
Pyrazolones 7a-k, partioned into 11 different vessels (1 mmol), were placed in the Büchi Syncore
®
 
and dissolved in dioxane (10 mL). Ca(OH)2 (2 equiv/mol) and p-chlorobenzoyl chloride (1 
equiv/mol) were then added. The reaction mixtures were refluxed at 300 rpm for 3 h. The cooled 
solutions were evaporated in parallel under vacuum to dryness. 3N HCl was added to precipitate 
crude compounds 8a-k which were then filtered in parallel and recrystallized from EtOH. 
8a: Yield 58%. 
1
H NMR ((CD3)2SO):  7.97-7.84 (m, 4H, Ph), 7.63-7.39 (m, 5H, Ph), 6.96 (br s, 
1H, OH). MS: m/z 367 (M
+
), 389 (M+Na). Anal. for C17H10ClF3N2O2 Calcd %: C, 55.68; H, 2.75; 
N, 7.64. Found %: C, 55.79; H, 2.89; N, 7.89.
9b
 
8b: Yield 54%. 
1
H NMR ((CD3)2SO):  7.68-7.66 (m, 4H, Ph), 7.58-7.23 (m, 5H, Ph), 3.35 (1H, m, 
CH3CHCH3), 1.12 (6H, d, J = 6.8 Hz, CH3CHCH3). MS: m/z 342 (M
+
), 364 (M+Na). Anal. for 
C19H17ClN2O2 Calcd %: C, 66.96; H, 5.03; N, 8.22. Found %: C, 67.07; H, 5.23; N, 8.45. 
8c: Yield 70%. 
1
H NMR ((CD3)2SO):  7.74-7.16 (m, 14H, Ph). MS: m/z 375 (M
+
), 397 (M+Na). 
Anal. for C22H15ClN2O2 Calcd %: C, 70.50; H, 4.03; N, 7.47. Found %: C, 70.69; H, 4.22; N, 7.65. 
8d: Yield 61%. 
1
H NMR ((CD3)2SO):   7.98-7.84 (m, 4H, Ph), 7.68-7.47 (m, 4H, Ph), 6.94 (br s, 
1H, OH). MS: m/z 402 (M
+
), 424 (M+Na). Anal. for C17H9Cl2F3N2O2 Calcd %:  C, 50.90; H, 2.26; 
N, 6.98. Found %: C, 50.99; H, 2.45; N, 6.89.
9b
   
8e: Yield 63%. 
1
H NMR ((CD3)2SO):  7.75-7.69 (m, 4H, Ph), 7.51-7.46 (m, 4H, Ph), 3.22 (1H, m, 
CH3CHCH3), 1.17 (6H, d, J = 6.9 Hz, CH3CHCH3). MS: m/z 376 (M
+
), 398 (M+Na). Anal. for 
C19H16Cl2N2O2 Calcd %: C, 60.81; H, 4.30; N, 7.47. Found %: C, 60.99; H, 4.56; N, 7.59. 
8f: Yield 69%. 
1
H NMR ((CD3)2SO):  7.88-7.52 (m, 6H, Ph), 7.36-7.21 (m, 7H, Ph). MS: m/z 410 
(M
+
), 432 (M+Na). Anal. for C22H14Cl2N2O2 Calcd %: C, 64.56; H, 3.45; N, 6.84. Found %: C, 
64.67; H, 3.67; N, 6.90. 
8g: Yield 35%. 
1
H NMR (CDCl3):  (ppm) 7.81-7.75 (2H, m, Ph),7.60-7.46 (6H, m, Ph), 2.09 (3H, 
s, CH3). MS: m/z 389-391 (M-1)
-
. Anal. for C17H12BrClN2O2 Calcd %:  C, 52.13; H, 3.09; N, 7.15. 
Found %: C, 52.23; H, 3.10; N, 7.16.    
8h: Yield 68%. 
1
H NMR (CDCl3):  7.70 (d, 2H, J = 8.5 Hz, Ph), 7.58 (d, 2H, J = 8.6 Hz, Ph), 7.47 
(d, 2H, J = 8.6 Hz, Ph), 7.25 (d, 2H, J = 8.5 Hz, Ph),  2.37 (s, 3H, CH3), 2.09 (s, 3H, CH3). MS: m/z 
327 (M
+
), 349 (M+Na). Anal. for C18H15ClN2O2 Calcd %:  C, 66.16; H, 4.63; N, 8.57. Found %: C, 
66.34; H, 4.87; N, 8.76.   
8i: Yield 68%. 
1
H NMR ((CD3)2SO):  7.68-7.59 (m, 4H, Ph), 7.34-7.20 (m, 9H, Ph), 2.33 (s, 3H, 
CH3). MS: m/z 389 (M
+
), 411 (M+Na). Anal. for C23H17ClN2O2 Calcd %:  C, 71.04; H, 4.41; N, 
7.20. Found %: C, 71.34; H, 4.65; N, 7.34.    
8j: Yield 61%. 
1
H NMR ((CD3)2SO):  7.67-7.65 (m, 2H, Ph), 7.49-7.45 (m, 4H, Ph), 7.28-7.26 (m, 
2H, Ph), 2.84 (1H, m, CH3CHCH3), 2.18 (s, 3H, CH3), 1.13 (6H, d, J = 6.7 Hz, CH3CHCH3). MS: 
m/z 355 (M
+
), 377 (M+Na). Anal. for C20H19ClN2O2 Calcd %:  C, 67.70; H, 5.40; N, 7.89. Found 
%: C, 67.89; H, 5.67; N, 7.94.   
8k: Yield 70%. 
1
H NMR ((CD3)2SO):  7.77-7.59 (m, 4H, Ph), 7.38-7.21 (m, 9H, Ph), 2.93 (1H, m, 
CH3CHCH3), 1.21 (6H, d, J = 6.8 Hz, CH3CHCH3). MS: m/z 417 (M
+
), 439 (M+Na). Anal. for 
C25H21ClN2O2 Calcd %:  C, 72.02; H, 5.08; N, 6.72. Found %: C, 72.34; H, 5.23; N, 6.87.   
 
Parallel synthesis of pyrazoles 9a-f.  
Compounds 1 and 2 (0.5 mmol),
4
 divided into 6 different vessels, were placed in the Büchi 
Syncore
®
 and dissolved in dry DMF (5 mL). NaH (2 equiv/mol) was added and the reaction 
mixtures were stirred at 300 rpm for 1 h. The appropriate benzyl chloride (or benzyl bromide) (1 
equiv/mol) and NaI (cat.) were then added and the resulting mixtures were stirred at rt at 300 rpm 
overnight. Water (5 mL) and AcOEt (5 mL) were added and the resulting mixtures were stirred for 
1 h. The organic layers were then filtered out in parallel and evaporated to dryness to afford crude 
compounds 9a-f, which were purified by flash chromatography (hexanes: ethyl acetate 4:1) to 
afford the final products (20-73 % yield). 
 
9a: Yield: 50%. 
1
H NMR (CDCl3):  (ppm) 7.73 (2H, d, J=8.13 Hz, Ph), 7.38-7.28 (5H, m, Ph), 
6.90 (2H, d, J=7.71 Hz, Ph), 6.83-6.81 (2H, m, Ph), 6.81-6.79 (2H, m, Ph),  4.82 (2H, s, NCH2Ph), 
2.57 (3H, s, CH3). MS: m/z 421-423 (M+1)
+
; 443-445 (M+Na)
+
; 863 (2M+Na)
+
. Anal. for 
C24H18ClFN2O2 Calcd. %: C, 68.49; H, 4.31; N, 6.66. Found %: C, 68.63; H, 4.32; N, 6.67.    
9b: Yield: 20%. 
1
H NMR (CDCl3):  (ppm) 7.76 (2H, d, J=8.33 Hz, Ph), 7.39-7.7.15 (10H, m, Ph), 
6.88-6.86 (2H, m, Ph), 4.88 (2H, s, NCH2Ph), 2.61 (3H, s, CH3). MS: m/z 403-405 (M+1)
+
; 425-
427 (M+Na)
+
; 827-829 (2M+Na)
+
. Anal. for C24H19ClN2O2 Calcd %: C, 71.55; H, 4.75; N, 6.95. 
Found %: C, 71.76; H, 4.76; N, 6.97.  
9c: Yield: 60%. 
1
H NMR (CDCl3):  (ppm) 8.09 (2H, d, J=8.61 Hz, Ph), 7.75 (2H, d, J=8.52 Hz, 
Ph), 7.37-7.28 (5H, m, Ph), 7.13 (2H, d, J=7.7 Hz, Ph), 7.02 (2H, d, J=8.61 Hz, Ph), 4.94 (2H, s, 
NCH2Ph), 2.58 (3H, s, CH3). MS: m/z 448-450 (M+1)
+
; 470-472 (M+Na)
+
; 486 (M+K)
+
; 917-919-
918 (2M+Na)
+
. Anal. for C24H18ClN3O4 Calcd %: C, 64.36; H, 4.05; N, 9.38. Found %: C, 64.62; 
H, 4.06; N, 9.42.  
9d: Yield: 73%. 
1
H NMR (CDCl3):  (ppm) 7.75 (2H, d, J=8.28 Hz, Ph), 7.37-6.80 (10H, m, Ph), 
4.82 (2H, s, NCH2Ph), 2.60 (3H, s, CH3). MS: m/z 455-457 (M+1)
+
; 477-479 (M+Na)
+
; 933-931 
(2M+Na)
+
. Anal. for C24H17Cl2FN2O2 Calcd %: C, 63.31; H, 3.76; N, 6.15. Found %: C, 63.76; H, 
3.77; N, 6.16. 
9e: Yield: 20%. 
1
H NMR (CDCl3):  (ppm) 7.78 (2H, d, J=8.00 Hz, Ph), 7.41-7.13 (9H, m, Ph), 
6.92-6.90 (2H, m, Ph), 4.91 (2H, s, NCH2Ph), 2.66 (3H, s, CH3). MS: m/z 437-439 (M+1)
+
; 459-
461 (M+Na)
+
; 895-897 (2M+Na)
+
. Anal. for C24H18Cl2N2O2 Calcd %: C, 65.91; H, 4.15; N, 6.41. 
Found %: C, 66.04; H, 4.16; N, 6.42.    
9f: Yield: 30%. 
1
H NMR (CDCl3):  (ppm) 8.13 (2H, d, J=8.75 Hz, Ph), 7.77 (2H, d, J=7.99 Hz, 
Ph), 7.40-7.31 (4H, m, Ph), 7.15-7.06 (4H, m, Ph), 4.97 (2H, s, NCH2Ph), 2.61 (3H, s, CH3). MS: 
m/z 504-506 (M+Na)
+
; 987 (2M+Na)
+
. Anal. for C24H17Cl2N3O4 Calcd %: C, 59.77; H, 3.55; N, 
8.71. Found %: C, 59.95; H, 3.56; N, 8.73.    
 
6. Microbiological assays 
 
Mycobacterial strain. M. tuberculosis H37Rv ATCC 27294 was used in this study. It was 
maintained on Löwenstein-Jensen (bioMérieux, Marcy l’Étoile, France) agar slants until needed. 
 
Antimicrobial susceptibility testing. MICs were determined by a standard twofold agar dilution 
method. Briefly, 1 mL of Middlebrook 7H11 agar (Becton Dickinson BBL, Sparks, MD) 
supplemented with 10% oleic acid-albumin-dextrose-catalase enrichment containing the testing 
compounds in 24-multiwell plates at concentrations ranging between 0.0312 and 64 g/mL, was 
inoculated with 10 L of a suspension containing M. tuberculosis H37Rv 1.5 x 105 cfu/mL grown 
on Middlebrook 7H9 broth (Difco Laboratories, Detroit, MI) supplemented with 10% albumin-
dextrose-catalase enrichment. Final inoculum was  1.5 x 10
3
 per well and was obtained as described 
previously.
13
 Plates were incubated for 21 to 28 days and MICs were read as minimal 
concentrations of compounds completely inhibiting visible growth of mycobacteria. 
 
7. Computational details 
Computational analysis was performed by means of the Catalyst software package, version 4.10.
10
  
All the compounds were built using the 2D/3D sketcher of the program. A representative family of 
conformations was generated for each molecule using the CHARMm force field implemented in 
Catalyst, together with the Poling algorithm and the best quality conformational analysis 
method.
15,16
 Conformational diversity was emphasized by selection of the conformers that fell 
within a 20 kcal/mol range above the lowest-energy conformation. The Compare/Fit command in 
the Hypothesis Generation workbench was used to analyse the mapping mode of compounds within 
the pharmacophoric model. In particular, the Best Fit option was applied, which manipulates 
conformers within the specified energy threshold to minimize the distances between hypothesis 
features and mapped atoms in the molecule. 
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